RCMNY
TXMD icon

Rubric Capital Management (New York)’s TherapeuticsMD TXMD Stock Holding History

Rubric Capital Management (New York)’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-308
Closed -$18K – 67
2021
Q2 		$18K Buy
+308
New +$18.7K ﹤0.01% 63

Other funds holding TXMD

CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rubric Capital Management (New York)'s TXMD Position: Q1 2026 in Review

Rubric Capital Management (New York) held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 1,192,191 shares worth $2.41M. The position accounts for 0.03% of the portfolio, ranked #81.

Rubric Capital Management (New York) first reported a position in TXMD in Q4 2018 and has held it in 30 quarters since. The position peaked at $26.7M in Q4 2019. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Rubric Capital Management (New York) held 1,192,191 shares of TherapeuticsMD worth $2.41M as of Q1 2026.
  • Rubric Capital Management (New York) left its TherapeuticsMD share count unchanged in Q1 2026.
  • TherapeuticsMD made up 0.03% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #81 holding.
  • Rubric Capital Management (New York) first reported a position in TherapeuticsMD in Q4 2018 and has held it in 30 quarters since.
  • Rubric Capital Management (New York)'s TherapeuticsMD position peaked at $26.7M in Q4 2019.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.